Selective serotonin reuptake inhibitors in the treatment of panic disorder and agoraphobia

International Clinical Psychopharmacology

Volumn 15, Issue SUPPL. 2, 2000, Pages

  Bakker, A ^a   Van Balkom, A J L M ^a   Van Dyck, R ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Agoraphobia; Antidepressants; Panic disorder; SSRIs

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BROFAROMINE; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

AGORAPHOBIA; BEHAVIOR THERAPY; CLINICAL PRACTICE; COGNITIVE THERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DEPRESSION; HUMAN; PANIC; PRIORITY JOURNAL; PSYCHOTHERAPY;

EID: 0033736238     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200008002-00005     Document Type: Conference Paper

References (33)

1. Follow-up on the treatment of panic disorder with or without agoraphobia: A quantitative review
2. Consensus statement on panic disorder from the international consensus group on depression and anxiety
3. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder
4. Clonazepam in the treatment of panic disorder: A double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response
5. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder
6. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: A meta-analysis
7. Drug treatment of panic disorder
8. Treatment of panic disorder with agoraphobia: Comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone
9. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline
10. Serotonin function in panic disorder: A double-blind placebo-controlled study with fluvoxamine and ritanserin
11. Effect of a serotonin uptake inhibitor in anxiety disorders: A double-blind comparison of clomipramine and fluvoxamine
12. Effect of a selective serotonin uptake inhibitor in agoraphobia with panic attacks
13. The use of newer antidepressants for panic disorder
14. Effect of fluvoxamine on panic disorder
15. A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: A review of the literature
16. Psychiatric reaction patterns to imipramine
17. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder
18. Efficacy studies of paroxetine in panic disorder
19. Outcome assessment and clinical improvement in panic disorder: Evidence from a randomized controlled trial of fluoxetine and placebo
20. Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder
21. Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study
22. Clomipramine treatment of panic disorder: Pros and cons
23. Methodologies and outcomes from the sertraline multicenter flexible-dose trials
24. Fluvoxamine, placebo, and cognitive behaviour therapy used alone and in combination in the treatment of panic disorder and agoraphobia
25. The role of SSRIs in panic disorder
26. Moclobemide for anxiety disorders: A focus on moclobemide for panic disorder
27. Growing placebo response rate: The problem in recent therapeutic trials?
28. Meta-analysis on the treatment of panic disorder with agoraphobia: Review and re-examination
29. A meta-analysis of the treatment of panic disorder with or without agoraphobia: A comparison of psychopharmacological, cognitive-behavioral, and combination treatments
30. A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder
31. The effect of citalopram in panic disorder
32. Developments in the drug treatment of panic disorder: What is the place of the selective serotonin reuptake inhibitors?